The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study

Elizabeth Schneider; Elizabeth Martin; Pia Rotshtein; Kasim L Qureshi; Samuel R Chamberlain; Maartje S Spetter; Colin T Dourish; Suzanne Higgs

doi:10.1038/s41398-021-01770-4

The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study

Elizabeth Schneider, Elizabeth Martin, Pia Rotshtein, Kasim L Qureshi, Samuel R Chamberlain, Maartje S Spetter, Colin T Dourish, Suzanne Higgs

Research output: Contribution to journal › Article › peer-review

69 Downloads (Pure)

Abstract

Lisdexamfetamine dimesylate (LDX) is the only drug currently approved by the FDA for the treatment of Binge-Eating Disorder (BED), but little is known about the behavioural mechanisms that underpin the efficacy of LDX in treating BED. We examined the behavioural and neural effects of an acute dose of LDX (50 mg) in 22 women with binge-eating symptomatology using a randomised, crossover, double-blind, placebo-controlled experimental medicine design. LDX reduced self-reported appetite ratings and intake of both a pasta meal and a palatable cookie snack. LDX also decreased the eating rate of pasta but not of cookies and reduced self-reported liking ratings for pasta at the end of the meal. When viewing food pictures during an fMRI scan, LDX reduced activity bilaterally in the thalamus. LDX enhanced sustained attention and reduced impulsive responding in a continuous performance task but had no effect on emotional bias or working memory. These results suggest the observed effects of LDX on food intake (and by implication the efficacy of LDX in treating BED) may be related to the actions of the drug to enhance satiety, reduce food-related reward responding when full and/or increase cognitive control. Novel pharmacotherapies for BED might be most effective if they have a broad spectrum of effects on appetite, reward and cognition.

Original language	English
Article number	9
Pages (from-to)	8
Journal	Translational Psychiatry
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41398-021-01770-4
Publication status	Published - 10 Jan 2022

Bibliographical note

Funding Information:
Role of Funding Source. Funding for this work was provided by BBSRC Grant UK to SH grant number: BB/N008847/1. The BBSRC had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Colin T Dourish is a Director and Co-Owner of P1vital Limited and a Director and Co-Owner of P1vital Products Limited. Prof. Chamberlain’s role in this study was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z & 110049/Z/15/A). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Prof. Chamberlain receives honoraria from Elsevier for editorial work. He previously consulted for Promentis.

Publisher Copyright:
© 2021, The Author(s).

Keywords

Attention Deficit Disorder with Hyperactivity
Binge-Eating Disorder
Biomedical Research
Central Nervous System Stimulants
Cognition
Dextroamphetamine
Double-Blind Method
Feeding Behavior
Female
Humans
Lisdexamfetamine Dimesylate
Reward
Treatment Outcome

Access to Document

10.1038/s41398-021-01770-4Licence: Creative Commons: Attribution (CC BY)

schneidere2022effectsFinal published version, 1.01 MBLicence: Creative Commons: Attribution (CC BY)

Interactions between metabolic, cognitive and reward processes in appetite
Rotshtein, P. & Higgs, S.
3/10/16 → 1/10/20
Project: Research Councils

Cite this

Schneider, E., Martin, E., Rotshtein, P., Qureshi, K. L., Chamberlain, S. R., Spetter, M. S., Dourish, C. T., & Higgs, S. (2022). The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study. Translational Psychiatry, 12(1), 8. Article 9. https://doi.org/10.1038/s41398-021-01770-4

@article{c91cc2a03dc047d1a12720fedc6107e7,

title = "The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study",

abstract = "Lisdexamfetamine dimesylate (LDX) is the only drug currently approved by the FDA for the treatment of Binge-Eating Disorder (BED), but little is known about the behavioural mechanisms that underpin the efficacy of LDX in treating BED. We examined the behavioural and neural effects of an acute dose of LDX (50 mg) in 22 women with binge-eating symptomatology using a randomised, crossover, double-blind, placebo-controlled experimental medicine design. LDX reduced self-reported appetite ratings and intake of both a pasta meal and a palatable cookie snack. LDX also decreased the eating rate of pasta but not of cookies and reduced self-reported liking ratings for pasta at the end of the meal. When viewing food pictures during an fMRI scan, LDX reduced activity bilaterally in the thalamus. LDX enhanced sustained attention and reduced impulsive responding in a continuous performance task but had no effect on emotional bias or working memory. These results suggest the observed effects of LDX on food intake (and by implication the efficacy of LDX in treating BED) may be related to the actions of the drug to enhance satiety, reduce food-related reward responding when full and/or increase cognitive control. Novel pharmacotherapies for BED might be most effective if they have a broad spectrum of effects on appetite, reward and cognition.",

keywords = "Attention Deficit Disorder with Hyperactivity, Binge-Eating Disorder, Biomedical Research, Central Nervous System Stimulants, Cognition, Dextroamphetamine, Double-Blind Method, Feeding Behavior, Female, Humans, Lisdexamfetamine Dimesylate, Reward, Treatment Outcome",

author = "Elizabeth Schneider and Elizabeth Martin and Pia Rotshtein and Qureshi, {Kasim L} and Chamberlain, {Samuel R} and Spetter, {Maartje S} and Dourish, {Colin T} and Suzanne Higgs",

note = "Funding Information: Role of Funding Source. Funding for this work was provided by BBSRC Grant UK to SH grant number: BB/N008847/1. The BBSRC had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Colin T Dourish is a Director and Co-Owner of P1vital Limited and a Director and Co-Owner of P1vital Products Limited. Prof. Chamberlain{\textquoteright}s role in this study was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z & 110049/Z/15/A). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Prof. Chamberlain receives honoraria from Elsevier for editorial work. He previously consulted for Promentis. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2022",

month = jan,

day = "10",

doi = "10.1038/s41398-021-01770-4",

language = "English",

volume = "12",

pages = "8",

journal = "Translational Psychiatry",

issn = "2158-3188",

publisher = "Nature Publishing Group",

number = "1",

}

Schneider, E, Martin, E, Rotshtein, P, Qureshi, KL, Chamberlain, SR, Spetter, MS, Dourish, CT & Higgs, S 2022, 'The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study', Translational Psychiatry, vol. 12, no. 1, 9, pp. 8. https://doi.org/10.1038/s41398-021-01770-4

The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study. / Schneider, Elizabeth; Martin, Elizabeth; Rotshtein, Pia et al.
In: Translational Psychiatry, Vol. 12, No. 1, 9, 10.01.2022, p. 8.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms

T2 - an experimental medicine study

AU - Schneider, Elizabeth

AU - Martin, Elizabeth

AU - Rotshtein, Pia

AU - Qureshi, Kasim L

AU - Chamberlain, Samuel R

AU - Spetter, Maartje S

AU - Dourish, Colin T

AU - Higgs, Suzanne

N1 - Funding Information: Role of Funding Source. Funding for this work was provided by BBSRC Grant UK to SH grant number: BB/N008847/1. The BBSRC had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Colin T Dourish is a Director and Co-Owner of P1vital Limited and a Director and Co-Owner of P1vital Products Limited. Prof. Chamberlain’s role in this study was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z & 110049/Z/15/A). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Prof. Chamberlain receives honoraria from Elsevier for editorial work. He previously consulted for Promentis. Publisher Copyright: © 2021, The Author(s).

PY - 2022/1/10

Y1 - 2022/1/10

N2 - Lisdexamfetamine dimesylate (LDX) is the only drug currently approved by the FDA for the treatment of Binge-Eating Disorder (BED), but little is known about the behavioural mechanisms that underpin the efficacy of LDX in treating BED. We examined the behavioural and neural effects of an acute dose of LDX (50 mg) in 22 women with binge-eating symptomatology using a randomised, crossover, double-blind, placebo-controlled experimental medicine design. LDX reduced self-reported appetite ratings and intake of both a pasta meal and a palatable cookie snack. LDX also decreased the eating rate of pasta but not of cookies and reduced self-reported liking ratings for pasta at the end of the meal. When viewing food pictures during an fMRI scan, LDX reduced activity bilaterally in the thalamus. LDX enhanced sustained attention and reduced impulsive responding in a continuous performance task but had no effect on emotional bias or working memory. These results suggest the observed effects of LDX on food intake (and by implication the efficacy of LDX in treating BED) may be related to the actions of the drug to enhance satiety, reduce food-related reward responding when full and/or increase cognitive control. Novel pharmacotherapies for BED might be most effective if they have a broad spectrum of effects on appetite, reward and cognition.

AB - Lisdexamfetamine dimesylate (LDX) is the only drug currently approved by the FDA for the treatment of Binge-Eating Disorder (BED), but little is known about the behavioural mechanisms that underpin the efficacy of LDX in treating BED. We examined the behavioural and neural effects of an acute dose of LDX (50 mg) in 22 women with binge-eating symptomatology using a randomised, crossover, double-blind, placebo-controlled experimental medicine design. LDX reduced self-reported appetite ratings and intake of both a pasta meal and a palatable cookie snack. LDX also decreased the eating rate of pasta but not of cookies and reduced self-reported liking ratings for pasta at the end of the meal. When viewing food pictures during an fMRI scan, LDX reduced activity bilaterally in the thalamus. LDX enhanced sustained attention and reduced impulsive responding in a continuous performance task but had no effect on emotional bias or working memory. These results suggest the observed effects of LDX on food intake (and by implication the efficacy of LDX in treating BED) may be related to the actions of the drug to enhance satiety, reduce food-related reward responding when full and/or increase cognitive control. Novel pharmacotherapies for BED might be most effective if they have a broad spectrum of effects on appetite, reward and cognition.

KW - Attention Deficit Disorder with Hyperactivity

KW - Binge-Eating Disorder

KW - Biomedical Research

KW - Central Nervous System Stimulants

KW - Cognition

KW - Dextroamphetamine

KW - Double-Blind Method

KW - Feeding Behavior

KW - Female

KW - Humans

KW - Lisdexamfetamine Dimesylate

KW - Reward

KW - Treatment Outcome

U2 - 10.1038/s41398-021-01770-4

DO - 10.1038/s41398-021-01770-4

M3 - Article

C2 - 35013131

SN - 2158-3188

VL - 12

SP - 8

JO - Translational Psychiatry

JF - Translational Psychiatry

IS - 1

M1 - 9

ER -

The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Projects

Interactions between metabolic, cognitive and reward processes in appetite

Cite this